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Abstract
Serotonin receptors are prevalent throughout the nervous system and the periphery, and remain 
one of the most lucrative and promising drug discovery targets for disorders ranging from 
migraine headaches to neuropsychiatric disorders such as schizophrenia and depression. There are 
14 distinct serotonin receptors, of which 13 are G protein coupled receptors (GPCRs), which are 
targets for approximately 40% of the approved medicines. Recent crystallographic and 
biochemical evidence has provided a converging understanding of the basic structure and 
functional mechanics of GPCR activation. Currently, two GPCR crystal structures exist for the 
serotonin family, the 5-HT1B and 5-HT2B receptor, with the antimigraine and valvulopathic drug 
ergotamine bound. The first serotonin crystal structures not only provide the first evidence of 
serotonin receptor topography but also provide mechanistic explanations into functional selectivity 
or biased agonism. This review will detail the findings of these crystal structures from a molecular 
and mutagenesis perspective for driving rational drug design for novel therapeutics incorporating 
biased signaling.
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1. Introduction
Serotonin or 5-hydroxytryptamine (5-HT) remains one of the most widely studied chemical 
messengers. Serotonin produces a myriad of physiological effects in humans, mediated 
through 14 distinct receptor subtypes, of which 13 are G protein coupled receptors (GPCRs), 
and one ligand-gated cation channel (Berger et al., 2009; Hoyer et al., 1994). 5-HT receptors 
have evolved over the course of 700–800 million years (Kroeze and Roth, 1998; Peroutka 
and Howell, 1994). In the human central nervous system (CNS) alone, all the serotonin 
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receptor subtypes, with the exception of 5-HT5b, are expressed, and they are involved in the 
modulation of sleep-wake cycles, emesis, appetite, mood, memory, breathing (Ray et al., 
2011), cognition, and many other functions (Berger et al., 2009; Meltzer and Roth, 2013). 
Much of the serotonin in the body, however, is not found in the CNS, rather in the 
gastrointestinal (GI) tract, where it causes peristalsis through either smooth muscle 
contraction or enteric nerve depolarization (Gershon et al., 1990). Lesser known, but 
historically important, serotonin is found in the blood, isolated from platelets in the serum, 
where it is involved in blood coagulation and vasoconstriction, a function which led to its 
name “sero” (from serum) and “tonin” (to induce contraction)(Rapport et al., 1948). Not 
surprisingly, more than 125,000 published articles as of 2014 (pubmed search) have been 
published on serotonin and its receptors.
Much research regarding serotonin has been in the area of neuropsychiatric drug discovery 
in treatment of affective disorders, where there continues to be an extreme interest in the 
design of more efficacious pharmaceuticals. Drugs either targeting serotonin receptors or 
serotonin itself represent a large share of the top selling pharmaceuticals in the past decade, 
with more being approved for future use. This is most evident with antidepressants such as 
SSRIs (serotonin-selective reuptake inhibitors) dominating the drug market, with over $11 
billion in sales in 2008 alone, and Cymbalta (duloexetine), a dual serotonin-norepinephrine 
reuptake inhibitor (SNRI), being in the top 10 drugs sold in the US in 2012 (Lindsley, 2013). 
Additionally, newer antipsychotics, such as aripiprazole (Abilify) and quetiapine (Seroquel), 
which have partial agonist activity and/or antagonist activity at serotonin receptors, were 
also in the top 10 drugs sold in the US. Recently, newer SNRIs are being approved by the 
FDA with an indication to treat depression, including the approved levomilnacipran 
(Fetzima), and SSRIs with direct agonist activity at the 5-HT1A receptor have been approved 
by the FDA including vilazodone (Viibryd) and vortioxetine (Brintellix) for treatment of 
major depressive disorder (Celada et al., 2013). There is, however, a need for the discovery 
of more efficacious CNS pharmaceuticals with reduced side effects associated with off-
target activity. For example, agents for Parkinson’s disease, such as pergolide and 
bromocriptine, were discontinued in the US because of their ability to induce cardiac valve 
hypertrophy, which has been linked to off-target agonist action at the 5-HT2B receptor 
(Horvath et al., 2004; Roth, 2007; Rothman et al., 2000; Setola et al., 2003).
In addition to drug selectivity, the concept of functional selectivity (Urban et al., 2007) in 
pharmacology has revolutionized the drug discovery process with recent findings 
highlighting that functionally selective β-arrestin biased drugs can show efficacy in 
preclinical models of schizophrenia (Allen et al., 2011), and β-arrestin biased angiotensin II 
type 1 compounds are currently in Phase 2 clinical trials for treatment of congestive heart 
failure (Soergel et al., 2013). Thus, rational drug design of newer serotonin receptor drugs 
incorporating ligand bias appears to be a fruitful area of drug development that potentially 
could be facilitated by insights into the structure and function of their respective targets.
Recently, there has been a GPCR structural “renaissance” with crystal structures from 
several representative receptor classes being solved, including rhodopsin (Palczewski et al. 
2000), β2 adrenergic (Cherezov et al., 2007), β1 adrenergic (Warne et al., 2008), A2A 
adenosine (Jaakola et al., 2008), H1 histamine (Shimamura et al., 2011), D3 dopamine 
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(Chien et al., 2010), smoothened (Wang et al., 2013b), CXCR4 (Wu et al., 2010), 
sphingosine 1-phosphate (Hanson et al., 2012), protease-activated receptor 1(Zhang et al., 
2012), M2 muscarinic (Haga et al., 2012), M3 muscarinic (Kruse et al., 2012), mu opiate 
(Manglik et al., 2012), delta opiate (Granier et al., 2012), kappa opiate (Wu et al., 2012), 
nociceptin/orphanin (Thompson et al., 2012), and recently the 5-HT1B and 5-HT2B serotonin 
receptors (Wacker et al., 2013; Wang et al., 2013a). These receptor crystal structures 
provide a wealth of structural information for the design of more receptor subtype selective 
agents, and also provide insights into the chemo-mechanical processes involved in GPCR 
activatation (Mustafi and Palczewski, 2009). Thus GPCR structures likely will serve 
medicinal chemists and pharmacologists to design new functionally selective drugs as 
potential therapies or pharmacological tools (Kenakin and Christopoulos, 2013).
The recent publications of two serotonin receptor crystal structures in complex with 
ergotamine (ERG), a former antimigraine agent, has opened up two major discussions 
relevant to the serotonin field, which concern the molecular basis for 1) serotonin receptor 
subtype recognition and 2) functional selectivity. The 5-HT1B crystal structure illustrates the 
molecular basis for the selectivity of antimigraine triptan drugs that are devoid of 5-HT2B 
receptor off-target activity, and the 5-HT2B crystal structure provides clues into the 
functional mechanics of a receptor in a β-arrestin biased state. These crystal structures not 
only further our understanding into serotonin’s therapeutic and off-target effects in the 
current drug discovery process, but also serve to refine our understanding of GPCRs in 
general.
This review will be divided into two major sections. The first part will provide a background 
and relevance of serotonin as it relates to our current understanding of its actions in the body 
and in medicine, with a particular emphasis on the 5-HT1B and 5-HT2B receptors. The 
second part will focus on the structural importance of the recently published serotonin 
receptor crystal structures, especially as it relates to our current understanding of GPCR 
structure and function. The final section will suggest future areas for the development of our 
understanding of functional selectivity and biased agonism.
2. Historic aspects and significance
2.1 Discovery of 5-HT and 5-HT receptors
Serotonin was actually discovered independently by two laboratories, Vittorio Erspamer’s 
lab in Rome, Italy (Erspamer and Boretti, 1950) and Irvine Page’s lab at the Cleveland 
Clinic (Rapport et al., 1948). Although the action of serotonin is usually associated with 
CNS function, the majority of serotonin actually resides in the gastrointestinal (GI) tract, 
produced by enterochromaffin cells lining the lumen of the gut, where it causes increased 
peristaltic activity (Beleslin and Varagic, 1958). It was from the GI tract that Vittorio 
Erspamer first isolated serotonin in 1938, a substance that he deduced was an indole amine, 
which he named enteramine (Erspamer and Asero, 1952). Years later in 1948, a substance in 
blood serum that produced vasoconstriction was isolated by Maurice Rapport, Arda Green, 
and Irvine Page of the Cleveland Clinic (Rapport et al., 1948; Rapport et al., 1947), which 
was later named serotonin (“sero” serum, “tonin” constrict). It wasn’t until 1953, however, 
when Betty Twarog in Irvine Page’s lab analyzed brain extracts using a serotonin-sensitive 
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mollusk bioassay (Twarog and Page, 1953), an assay initially discovered by Erspamer 
(Erspamer and Ghiretti, 1951), that the presence of serotonin in brain extract was 
recognized. Interestingly, Erspamer had initially posited an indole nucleus being contained 
in enteramine’s structure, and later Rapport determined the structure of serotonin to be 5-
hydroxytryptamine (Rapport, 1949) shown in Figure 1.
Prior to the discovery of serotonin in the 1930’s, Sandoz pharmaceuticals had been 
marketing ergotamine, a drug that produced uterine contractions and was used to induce 
labor (Hofmann, 1978). Ergotamine is part of a larger class of compounds called ergolines, 
which includes ergopeptines like ergotamine, lysergamides like lysergic acid diethylamide 
(LSD), and ergoclavines, all of which retain the indole nucleus in their structures (Figure 1). 
By 1938, research into other ergolines at Sandoz by the Swiss chemist, Albert Hofmann, 
who under Arthur Stoll, synthesized several hundred analogs of ergotamine. Albert 
Hofmann is often famously noted for the discovery of LSD, which serendipitously had been 
discovered by him via synthesizing analogs of ergotamine and changing the amide 
substituent into simpler alkyl chains, a subclass of ergolines usually termed lysergamides. 
LSD, however, did not satisfy the pharmacological profile using rat uterus contraction 
assays, and interest in it as an obstetric drug waned. Hofmann, however, was compelled to 
re-synthesize LSD in 1943 based on the diethyl substitution found in a known analeptic drug 
coramine (nicotinic acid diethylamide, forming the D-ring of LSD, Figure 1), which was 
known to induce CNS stimulation and increased respiration. On April 16th 1943, Hofmann 
experienced what he thought was a “mystical” experience around his newly synthesized 
LSD. Thinking he may have accidently ingested a small amount, three days later on April 
19th, he ingested what he thought was a small test dose, 0.25 mg or 250 μg, which today is 
known to be a substantial dose of LSD, and the unexpected effects were far beyond any 
respiratory or CNS stimulant as seen with coramine. Instead, they were “kaleidoscopic, 
fantastic images” and “alterations that I perceived in myself, in my inner being” (Hofmann, 
1980). From that time forward, the unique and powerful psychoactive properties that LSD 
can evoke became widely known.
Later in the 1940s, LSD was promoted as a research tool in the psychiatry, especially in 
understanding schizophrenia. Until then, the roots of schizophrenia’s etiology had been 
argued to be more nurture-based rather than nature-based, and attributed to improper 
parenting. LSD’s ability to induce transient thought disorders, perceptual and visual 
hallucinations, and delusions in certain individuals, however, began to spur more research 
into LSD’s pharmacological actions. After the structure of serotonin was published, a 
hypothesis was put forth that linked serotonin to several mental disorders (Woolley and 
Shaw, 1954). Woolley, who was almost completely blind from diabetes, conceived the 
importance of serotonin in mental disorders simply by realizing that the tryptamine scaffold 
of 5-HT was embedded within LSD’s structure (Figure 1). It wasn’t until much later, 
however, that the importance of serotonin receptors in schizophrenia and depression was 
fully appreciated.
LSD became a powerful tool at the disposal of pharmacologists to clarify the physiological 
actions of serotonin in whole tissue assays. John Gaddum pioneered the serotonin receptor 
pharmacology field by first discovering that LSD antagonized the action of 5-HT in these 
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tissues (Gaddum, 1953), which ultimately led to the classification of two types of serotonin 
receptors, then referred to as tryptamine receptors (Gaddum and Picarelli, 1957). In 
serotonin-induced contractions of guinea pig ileum, the D-type was designated as being 
sensitive to blockade by the irreversible antagonist, dibenzyline, also known as 
phenoxybenzamine, and the M-type was sensitive to blockade by morphine (Gaddum and 
Picarelli, 1957). In that study, Gaddum and Picarelli hypothesized that serotonin-induced 
contractions of the ileum by the D-type receptors acted in smooth muscle and the M-type 
acted in nerve ganglia. With only a delineation of serotonin receptors based on available 
pharmacological agents in animal tissues, much of serotonin receptor research waned for 
more than two decades.
In the 1970’s, the development of radioligands specifically to label receptors in animal 
tissue were developed, leading to the use of [3H]-LSD and [3H]-5-HT. Peroutka and Snyder 
(1979) used 3H-LSD to label two distinct receptor populations, one that had higher affinity 
for [3H]-5-HT, which they named 5-HT1, and another that had higher affinity for [3H]-
spiperone, which they named 5-HT2. The affinity for 5-HT at these receptor types was 
sensitive to the presence of guanine nucleotides (Peroutka et al., 1979), indicating that these 
receptors were likely G protein coupled. Later, it was found that 5-HT2 receptors were 
correlated with the actions of the previously named D-type receptor (Bradley et al., 1986). 
The M-type was then found to be a new serotonin receptor type, the 5-HT3 receptor, which 
was revealed to be a ligand-gated ion channel permeable to cations (Derkach et al., 1989), in 
contrast to the 5-HT1 and 5-HT2 receptors.
On the basis of selective agonist/antagonist ligand affinities, cloned sequence homology, and 
intracellular transduction mechanisms, serotonin receptors were reclassified into seven 
types, comprised of 14 subtypes (Hoyer et al. 1994). With this new classification system, 
much serotonin receptor research has flourished in the past 20 years, linking receptor 
distribution to physiological actions (Berger et al., 2009), and the design of subtype selective 
agents, which will be discussed in the next section.
2.2 5-HT receptors and canonical G protein signaling
According to the current classification system, there are seven types of 5-HT receptors, 5-
HT1-7. All 5-HT receptors are GPCRs with the exception of 5-HT3, which is a ligand-gated 
cation channel. Serotonin GPCRs couple to all three canonical signaling pathways through 
Gαi, Gαq/11, and Gαs, allowing this receptor family to modulate several biochemical 
signaling pathways, and leading to several physiological consequences, a discussion which 
is beyond the scope of this review, (but see Nichols and Nichols (2008) for a more 
comprehensive review).
The Gαi-coupled serotonin receptors encompass the 5-HT1 and 5-HT5 types. The 5-HT1 
subfamily, which is comprised of 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F subtypes, 
usually couple to Gαi(2) leading to inhibition of adenylyl cyclase and a decrease of 
intracellular cAMP (Bockaert et al., 1987; Lin et al., 2002). There is no 5-HT1C receptor 
because this subtype was re-designated the 5-HT2C receptor based on its functional Gq 
coupling. In this subfamily, the 5-HT1A receptor is expressed as both a pre-synaptic receptor 
in the raphe nuclei, where it serves to inhibit further release of CNS serotonin, and as a post-
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synaptic receptor in medial prefrontal cortex and other cortical areas to modulate dopamine 
release (Altieri et al., 2013; Bockaert et al., 1987). The 5-HT1A receptor has been implicated 
in anxiety, and as mentioned, novel anti-depressants and antipsychotics have begun to 
incorporate partial 5-HT1A agonist activity to enhance their efficacy in such diseases 
(Celada et al., 2013). Historically, the other 5-HT1 subtypes have been a focus on for the 
treatment of migraine and will be discussed in more detail in the following sections.
Little is known about the other Gαi-coupled serotonin receptor family, the 5-HT5 subfamily, 
which includes subtypes 5-HT5A and 5-HT5B. Only 5-HT5A has only been identified in 
human cortical layers and cerebellum (Pasqualetti et al., 1998). 5-HT5A has been shown to 
couple to Gαi in HEK cells (Hurley et al., 1998), and the selective 5-HT5A antagonist, 
SB-6995516, impairs memory (Gonzalez et al., 2013) and reduces acoustic startle (Curtin et 
al., 2013) in animal models. It has been suggested that the 5-HT5 receptor may be a 
therapeutic target in psychiatric disorders (Thomas, 2006), but to date, no selective agonists 
for this subtype exist to clarify its role.
The Gαq/11-coupled serotonin receptors include the 5-HT2 receptor subtypes, 5-HT2A, 5-
HT2B, and 5-HT2C. These receptors traditionally have been linked to Gq-related pathways, 
with activation of phospholipase C producing inositol triphosphate (IP3) and diacylglycerol 
(DAG), ultimately leading to an increase in intracellular calcium (Roth et al., 1984; Roth et 
al., 1998). There is evidence, however, that 5-HT2 receptors may exhibit G protein 
promiscuity, at least in cultured cell systems. For instance, inhibition of cAMP possibly 
through Gαi activation has been found to occur for 5-HT2A (Garnovskaya et al., 1995), and 
in the case of 5-HT2C with high expression levels (Lucaites et al., 1996). The 5-HT2A 
receptor is, by far, one of the most studied types of serotonin receptors owing to its 
widespread expression in the cortex (Willins et al., 1997), its involvement in the mechanism 
of hallucinogen action (see Nichols, 2004 for a review), and its implications and 
effectiveness as a receptor target in a handful of mental illnesses including schizophrenia, 
depression, and Tourette’s syndrome to name a few (Meltzer and Roth, 2013). The 5-HT2C 
is also widely distributed in the CNS (Mengod et al., 1996; Molineaux et al., 1989), and is 
also found in the ventral tegmental area negatively regulating dopamine release into nucleus 
accumbens (Di Giovanni et al., 2000). In fact, 5-HT2C-induced control of dopamine release 
has been proposed as a mechanism for some antidepressants (Millan et al., 2005), and 5-
HT2C antagonism may be responsible for the rewarding effects associated with these 
antidepressants (McCorvy et al., 2011). In addition, selective 5-HT2C agonists such as 
lorcaserin have shown efficacy as appetite suppressants (Thomsen et al., 2008) and are 
currently FDA approved (Hess and Cross, 2013), albeit with slight off-target effects at the 5-
HT2B receptor. Less well-known is the ability for 5-HT2 receptors to induce cell 
proliferation (Banasr et al., 2004), especially during tissue development, which will be 
further discussed as it pertains to off-target effects stemming from chronic 5-HT2B receptor 
activation.
The Gαs-coupled receptors include 5-HT4, 5-HT6, and 5-HT7. The 5-HT4 receptor as been 
shown to couple positively to adenylyl cyclase leading to increased levels of cAMP in 
guinea pig hippocampus (Bockaert et al., 1990), but may also result in increased calcium 
current, at least in human atrial myocytes (Ouadid et al., 1992) through a possible Gαq/11-
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coupled mechanism, which has been demonstrated in reconstituted systems (Ponimaskin et 
al., 2002). 5-HT4 receptor distribution varies widely in humans (Bonaventure et al., 2000), 
and select 5-HT4 activation can range from peristalsis in the gut (Kadowaki et al., 2002), to 
long-term potentiation (LTP) in hippocampus (Kulla and Manahan-Vaughan, 2002). 
Selective 5-HT4 knock-out mice exhibit stress-induced feeding disorders (Compan et al., 
2004). Selective 5-HT4 antagonists have been proposed to treat atrial fibrillation, irritable 
bowel syndrome, and urinary incontinence (Brudeli et al., 2013).
The 5-HT6 and 5-HT7 receptors, also Gαs-coupled, lead to an increase in cAMP, and are 
located in the CNS in the thalamus, hypothalamus, hippocampus, as well as the peripheral 
tissues. Many typical and atypical antipsychotics function as antagonists at cloned human 5-
HT6 and 5-HT7 receptors (Roth et al., 1994). There is evidence that selective 5-HT6 receptor 
antagonists, such as SB 271046, may also have cognitive enhancing properties, and may 
potentially be used for “add-on” therapy in conjunction with antipsychotics with low affinity 
for the 5-HT6 receptor (Roth et al., 2004). In addition, the 5-HT7 receptor is a potential drug 
target for depression and 5-HT7 receptor antagonism has been posited as necessary for 
amisulpride’s antidepressant (Abbas et al., 2009).
2.3 Non-canonical signaling and functional selectivity
In addition to canonical G protein signaling, GPCRs have also been found to be involved in 
non-canonical signaling via arrestin recruitment. Arrestin recruitment is a now appreciated 
as a mechanism in GPCR desensitization (Freedman and Lefkowitz, 1996) with clinical 
importance, especially regarding the tolerance and therapeutic utility of drugs (Violin et al., 
2014). GPCR desensitization occurs through GPCR kinase (GRK) recruitment and 
subsequent GPCR phosphorylation, which recruit β-arrestin1 and β-arrestin2 (also known as 
arrestin 2 and arrestin3, respectively) from which the binding of β-arrestin sterically 
prevents further G protein coupling, ultimately leading to desensitization (Krupnick and 
Benovic, 1998). The GPCR-β-arrestin complex can also target the GPCR to clathrin-coated 
pits (Krupnick et al., 1997), ultimately leading to internalization (Ferguson et al., 1996). 
GPCR internalization serves to control both the duration of the response and subsequent 
downstream signaling of the receptor-ligand complex. In addition to β-arrestins acting to 
attenuate G protein-dependent signaling, they can simultaneously initiate parallel, G protein-
independent signals (Lefkowitz and Shenoy, 2005). In view of the recent findings with non-
canonical arrestin-dependent signaling, it was previously thought that all agonist-receptor 
complexes stimulated all available signaling pathways to an equal extent. However, over the 
last decade, mounting evidence questions such a simplistic view.
The introduction and use of recombinant cell systems to express and measure specific 
receptor functional responses ushered in a new concept in pharmacology. Functional 
selectivity, sometimes called “agonist-directed trafficking” or more recently “ligand bias” 
was proposed to account for differences between two or more functional responses resulting 
from receptor activation by an agonist (Urban et al., 2007). The earliest conceptual 
framework for functional selectivity was proposed by Roth and Chuang (1987) to account 
for the phenomenon whereby one or more distinct biochemical transduction mechanisms 
may be activated by a single GPCR. Roth and Chuang (1987) also predicted that this 
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phenomenon would lead to the development of selective agonists for a particular receptor-
linked effector. Although functional selectivity exhibited by a given ligand may be system-
dependent in select cell lines, it has been well-established that functional selectivity reflects 
a ligand’s ability to select different conformations of the receptor, leading to a specific 
functional response over another (Kenakin, 2011), thus exhibiting conformational ligand 
bias. Selecting different conformations of the receptor may be key to the design of novel 
functionally selective agonists or antagonists with improved therapeutic potential over 
currently available medications; however our understanding of the molecular determinants 
that lead to biased agonism is not well-understood.
2.4 Serotonin 5-HT1B/1D receptors as a target for antimigraine medication
The first serotonin receptor to be cloned was the 5-HT1A receptor subtype (Kobilka et al., 
1987; Fargin et al., 1988). Interestingly, the 5-HT1 subtype exhibits a high degree of 
sequence and pharmacological similarity to the β-adrenergic receptors, and initially, it was 
thought to be a β-adrenergic receptor. Later, the 5-HT1B subtype was designated as a distinct 
receptor subtype from 5-HT1A on the basis that it did have high affinity for β-adrenergic 
receptor antagonists, but also had low affinity for spiperone (Pedigo et al., 1981; Nelson et 
al., 1981), whereas the 5-HT1A receptor binds spiperone with high affinity. Confusion still 
arose, however, over the existence of a human ortholog of 5-HT1B, because it exhibited 
responses in rodents (Hoyer et al., 1992) that were not similar in humans (Peroutka, 1994). 
Therefore, the 5-HT1Dα and 5-HT1Dβ receptor subtypes were classified to account for the 
human orthologs (Hoyer and Middlemiss, 1989). These two receptor subtypes were often 
confused as being pharmacologically distinct based on their ability to be activated by β-
adrenergic antagonists, such as propanolol and pindolol, where a single amino acid residue 
distinguishes this reverse pharmacology (Hamblin et al., 1992; Metcalf et al., 1992). This 
species difference will be discussed more in detail as it pertains to ligand selectivity in later 
sections.
As mentioned, the 5-HT1B/1D receptors have been shown to couple negatively to adenylyl 
cyclase resulting in lower intracellular cAMP, which has been demonstrated in vivo in 
substantia nigra (Bouhelal et al., 1988; Schoeffter et al., 1988), rabbit mesenteric artery 
(Hinton et al., 1999), and in transfected heterologous cell lines (Levy et al., 1992; Adham et 
al., 1992; Weinshank et al., 1992). Expression of 5-HT1B receptors is most prevalent in 
human cerebral arteries (Nilsson et al., 1999), where vasospasm has been implicated in the 
pathogenesis of migraine. In fact, activation of 5-HT1B/1D receptors in cerebral arteries by 
agonists causes vasoconstriction and has been posited as a therapeutic explanation for the 
antimigraine drugs.
Ergotamine, as discussed previously, was developed by Sandoz in the early 1930’s as a drug 
to induce pronounced uterine contraction, but ergotamine also shows vasoconstriction in the 
periphery as well as the cerebral arteries, suggesting therapeutic efficacy for migraine. The 
ergolines as a class of drugs, in general, are recognized as having several receptor targets 
including but not limited to 5-HT1A-1F, 5-HT2A-C, D1-5, as well as α1 and α2 adrenergic 
receptor types (Silberstein, 1997). The antimigraine effects, however, are likely mediated 
through agonist activity at the 5-HT1B, 5-HT1D and possibly 5-HT1F receptors present on 
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trigeminal nerve terminals (Ramirez Rosas et al., 2013). However, ergotamine as well as 
other antimigraine ergolines, such as dihydroergotamine and methysergide, suffer from 
acute side-effects due to vasoconstriction in the periphery leading to hypertension and 
coronary vasoconstriction. Ultimately with continued use, severe chronic side-effects can 
occur such as retroperitoneal fibrosis, pleuropulmonary fibrosis, and cardiac valvulopathy 
due to off-target activity at the 5-HT2B receptor (Roth, 2007; Rothman et al., 2000), which 
will be discussed in the next section.
In light of the serious side-effects and off-target activity of the ergolines, newer generation 
antimigraines incorporate an extended substitution on the tryptamine scaffold giving rise to 
the triptan class of drugs (Humphrey, 2008) (Figure 1). Triptans, such as sumatriptan, are 
extremely effective as antimigraine drugs potentially alleviating symptoms by 
vasoconstriction at cerebral arteries via 5-HT1B receptors and inhibition of proinflammatory 
neuropeptides in trigeminal fibers via 5-HT1D receptors. This class of medications avoids 
the cardiac valvulopathy and coronary vasoconstriction by having lower affinity at 5-HT2 
receptors, yet retaining selectivity and agonist activity at 5-HT1B/1D/1F receptors.
2.5 Serotonin 5-HT2B receptors as an off-target for cardiac valvulopathy
The rat 5-HT2B receptor, formerly known as the 5-HT2F receptor, was first cloned and 
characterized from the rat stomach fundus (Kursar et al., 1992; Foguet et al., 1992), which 
was previously discovered to cause contraction upon application of several trypamine 
agonists (Vane, 1959). The human 5-HT2B receptor was cloned from a placental genomic 
library (Kursar et al., 1994; Schmuck et al., 1994), and shares considerable homology with 
the previously cloned human 5-HT2A and 5-HT2C (formerly 5-HT1C) receptors. Functional 
activation of 5-HT2B was linked to inositol triphosphate (IP3) production in cultured cells 
(Wainscott et al., 1993) and calcium influx (Cox and Cohen, 1996), which leads to 
contraction of the stomach fundus. The ex vivo stomach fundus contraction assay was 
commonly used for detection of early serotoninergic agents including hallucinogenic drugs 
like LSD, but this assay likely reflects 5-HT2B receptor activity rather than 5-HT2A activity, 
which is more predictive for hallucinogenic agents (Nelson et al., 1999).
Expression patterns of 5-HT2B receptor using mRNA detection in mouse (Kursar et al., 
1994) showed high levels in the liver and kidney, with lower amounts in the heart and brain 
(Loric et al., 1992). Other mRNA expression studies confirmed the presence of 5-HT2B 
receptors in brain, specifically in the septal nuclei, dorsal hypothalamus and medial 
amygdala, with comparable levels detected in the stomach fundus (Duxon et al., 1997). 
Later, it was shown that the cardiovascular (Choi et al., 1994) and cardiac physiological 
functions of 5-HT2B were more prominent compared to its role in the CNS compared to 5-
HT2A and 5-HT2C receptor CNS functions (Bonhaus et al., 1995).
The hypothesis that 5-HT2B activation leading to cardiac hypertrophy gained prominence 
with the observation that the 5-HT2B knockout mouse demonstrated a lethal phenotype as a 
result of hypotrophy of the trabeculae cardiac muscles (Nebigil et al., 2000), which help 
control backflow of blood through the mitral (bicuspid) and tricuspid valves. Studies linked 
the involvement of the 5-HT2B receptor in cardiac hypertrophy through Gq activation and 
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concomitant phosphatidylinositol-3 kinase/Akt and extracellular signal-regulated kinase 
(ERK) 1/2 signaling pathways (Nebigil et al., 2003).
Coincidentally, the fenfluramine and phenteramine weight loss combination (fen-phen) 
marketed by Wyeth in the early 1990s resulted in patients exhibiting abnormal 
echocardiograms (Connolly et al., 1997), pulmonary hypertension (Brenot et al., 1993), 
among other cardiac valve deficiencies (Smith et al., 2009). Indeed, the major metabolite of 
fenfluramine, norfenfluramine (Figure 1), was found to have potent 5-HT2B agonist activity 
in Gq calcium release assays, whereas fenfluramine exhibits little activation (Fitzgerald et 
al., 2000; Roth, 2007; Rothman et al., 2000), indicating that the off-target effects of the 
fenfluramine metabolite, norfenfluramine, can lead to serious side-effects. This fact coupled 
with the finding that ergotamine also exhibits 5-HT2B agonist activity clearly indicates that 
the 5-HT2B receptor is an important off-target receptor to avoid in drug design. Finally, 
recent evidence regarding ergotamine’s pharmacological actions may be explained by its 
differential signaling profile at the 5-HT2B receptor (Huang et al., 2009), for which the 
major biochemical signaling pathway leading to cardiac valvulopathy remains unknown.
3. Structural features of serotonin 5-HT receptors
Since the cloning and annotation of the human genome, over 5% of the genome encodes for 
receptors, which more than 800 are GPCRs (Kroeze et al., 2003; Stevens et al., 2013). 
GPCRs are usually divided up into five classes and are named according to a representative 
prototypical receptor: rhodopsin (Class A), secretin (Class B), metabotropic glutamate 
(Class C), adhesion and smoothened/frizzled/taste (Fredriksson et al., 2003). Within these 
families, they share considerable sequence homology, and usually pharmacological 
similarities, but without evidence for an endogenous ligand, or for their physiological role, 
many are left orphaned and un-mined for their therapeutic potential (Armbruster and Roth, 
2005), or their side-effect profile (Allen and Roth, 2011). Lately, there has been an initiative 
to crystallize representative GPCRs from each class with the goal of understanding their 
structure-function relationships (Stevens et al., 2013), which will serve to expand drug 
development of novel therapeutic agents.
In the early 1900’s, when the terms “receptive substance” or “receptor” were introduced by 
John Langley and Paul Erlich, respectively (Langley, 1905; Ehrlich, 1913), to account for 
agonist versus antagonist drug action, pharmacologists believed that receptor activation was 
binary, that receptors contained an active state associated with agonist activity versus an 
inactive state, which was thought to be stabilized by antagonists. The phenomenon of partial 
agonism, however, began to question this notion, when it was found that ligands possess an 
“intrinsic” activity, which is to be contrasted with ligand affinity or the ability of a given 
ligand to bind to the receptor. Intrinsic activity or efficacy can reflect a ligand’s ability to 
maximally activate a receptor in a given pathway and is still poorly understood. Although 
receptor crystal structures provide an incredible amount of structural information about 
receptor conformations, they still do not provide a converging concept of intrinsic activity, 
especially with respect to different functional outcomes exhibited with biased ligands. 
However, in the case of the recent 5-HT1B and 5-HT2B crystal structures in complex with 
the same ligand, ergotamine, which exhibits a differential functional selectivity profile at 
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each of the receptors, it may now be possible to begin to uncover the molecular basis of 
functional selectivity.
This section of the review will offer a “tour” of the serotonin receptor crystal structures 
detailing findings from the conserved and non-conserved residues in the binding pocket to 
microdomain switches involved in the activation process. In addition, this review will also 
outline possible residues involved in the activation process that possibly lead to functional 
selectivity or biased signaling.
3.1 General GPCR features
Most of the well-studied GPCRs are in the rhodopsin-like family (Class A), which includes 
amine, peptide (e.g. opiate, vasopressin, angiotensin), and more than 200 types of olfactory 
receptors. The first Class A GPCR to be crystallized was bovine rhodopsin in an inactivated 
state covalently bound to cis-retinal (Palczewski et al., 2000), followed by a lower resolution 
opsin crystal structure, rhodopsin without retinal, in a photoactivated state (Salom et al., 
2006). These structures led to insights into the overall GPCR activation process; however, 
these structures without the G protein present in complex with the receptor lack the 
necessary information to provide a present mechanistic explanation needed for full receptor 
activation.
It wasn’t until the Kobilka and Stevens groups published the first amine GPCR crystal 
structure, the β2 adrenergic receptor (Rasmussen et al., 2007) followed by the structure of 
the β2 adrenergic receptor in complex with a G protein by Kobilka’s group (Rasmussen et 
al., 2011) that insights into the ligand-induced GPCR G protein activation were available. 
Using the β2 adrenergic receptor as a model for the GPCR activation process, crystal 
structures are now available with a variety of ligands including antagonist, inverse agonist, 
agonist, and full agonists to understand further the complex underpinnings of G protein 
agonism.
Together, these well-studied receptor systems revealed that Class A GPCRs contain a 
conserved architechture of seven transmembrane (TM) α-helical domains, and an 
intramembrane helix 8 (H8), which are connected by three intracellular loops (IL) and three 
extracellular loops (EL). Although the TM domains are relatively similar, except for slight 
differences in tilt and twist, there is considerable variability with the loops, especially EL2. 
In all Class A GPCRs, EL2 is tethered to TM3 by a conserved disulfide bridge between 
Cys3.25 and CysEL2. Joined by CysEL2, EL2 is essentially divided in two parts, the N-
terminus and C-terminus region, termed herein as EL2a and EL2b, respectively. With 
respect to the conserved disulfide bridge, the length of EL2b differs considerably between 
receptor types and even between subtypes, whereas EL2a is much longer and can adopt 
secondary structures such as the α-helix seen in the β2 adrenergic receptor crystal structure 
(Rasmussen et al., 2007). In addition, there are also conserved residues within each TM, but 
most of the differences between GPCRs of this class are in the binding pocket, which is 
lined by inward facing residues located in TM3, 5, 6, and 7, EL2 and EL3, and to a lesser 
extent, TM2. Differences in the binding pocket allow the selection of the ligand and hence, 
allow their homology to be associated with particular receptor types.
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For Class A GPCRs, Ballesteros and Weinstein conceived of a numbering system based on 
the most conserved residue within each TM designated as X.50, where X is the number of 
the TM and subsequent residues toward the C-terminus increase in number (X.51, X.52, 
etc.), and residues toward the N-terminus decrease (Ballesteros and Weinstein, 1995). 
Although there are other numbering systems that can be used (Baldwin, 1993; Schwartz, 
1994), the Ballesteros-Weinstein numbering system establishes a nomenclature that is better 
adapted to usage with visualization of crystal structures, and its use is indicated in 
superscripts when the relative receptor residue number is present.
Not surprisingly, each of the conserved residues in Class A GPCRs designated as X.50 have 
functional significance, to be discussed in detail in the following sections. Briefly, Asn1.50 
and Asp2.50 are important residues in the allosteric sodium site (Fenalti et al., 2014), 
Arg3.50 is part of the conserved DRY motif important in the activation process, Trp4.50 
arguably serves to stabilize the packing of TM2, 3, 4, and Pro5.50, Pro6.50, and Pro7.50 
introduce kinks into these helices and likely allow for dynamic movement toward the 
intracellular side. These residues are astounding in their conserved nature, which likely 
allows the formation of 7TM receptors scaffold to bind and function in a prototypical 
fashion.
3.2 Binding pocket
The binding pockets of the 5-HT1B and 5-HT2B receptors are strikingly similar in their 
overall architecture and exhibit little divergence in their residues. It is proposed that the 
orthosteric site, or the site of 5-HT binding, is occupied by the indole nucleus present in 
ergotamine (ERG), whereas the extended binding site is occupied by the peptide portion of 
ERG (Figure 2).
3.2.1 Orthosteric site—Class A GPCR orthosteric sites are relatively conserved in their 
overall architechture, where the majority of the orthosteric site occupies the extracellular 
portion of TM3, TM5, and TM6, and to a lesser extent TM2, TM7, and the C-terminal part 
of EL2. The orthosteric site, however, can differ depending on the crevice or depth, where 
histamine and muscarinic GPCR orthosteric sites occupy a deeper portion compared to 
serotonin and dopamine receptors. In TM3, the conserved aspartate (Asp3.32) serves to 
anchor the charged amine portion of the ligand, forming a stable salt bridge (Kristiansen et 
al., 2000) as shown in Figure 3A. Insights into the strength of this bond with mutagenesis 
reveal that D3.32A mutations severely reduce the affinity for amine-containing agonists and 
antagonists, but can be insensitive to certain ligands, especially in the case of 5-HT4 ligands 
(Claeysen et al., 2003). Residue Asp3.32 could be an advantageous starting point to prevent 
endogenous neurotransmitter binding for the design of novel engineered GPCRs including 
RASSLs (receptors activated solely by synthetic ligands) and DREADDs (designer 
receptors exclusively activated by designer drugs). DREADDs have the potential to 
illuminate the biochemical roles that GPCRs play in disease states and ultimately could 
translate into use as novel human therapeutics (Conklin et al., 2008; Urban and Roth, 2014).
One turn below the critical conserved Asp3.32, residue 3.36 also faces the binding pocket, 
where this residue is a Ser in 5-HT2 receptors, a Thr in 5-HT4 receptors, and a Cys in all 
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other 5-HT receptors, including the 5-HT1B receptor (Figure 3A). At least among 5-HT2 
receptors, this residue has been hypothesized to recognize the amine by possible 
coordination of the conserved aspartate (Almaula et al., 1996b). In this report, these authors 
clearly showed that alanine mutations of Ser3.36 in the 5-HT2A receptor detrimentally 
affected the affinity of primary amine ligands such as 5-HT and tryptamine, but for 
secondary or tertiary amine serotonin ligands, such as N,N-dimethyl tryptamine (DMT) and 
5-methoxy-DMT, the affinity was spared for the most part. This suggests that this residue 
likely is involved in recognition of the amine portion of the ligand and that the N-alkyl 
substitution of ligands can differentially be recognized dependent on the type of residue 
present.
Also, of importance in TM3 is a conserved Thr3.37, which is shown to engage the indole N-
H of ERG in both structures (Figure 3B). In both 5-HT1B and 5-HT2B structures, Thr3.37 
likely acts as a hydrogen bond acceptor, whereas the adjacent residue, Ala5.46, may be 
forming an additional van der Waals interaction with the N-H of the indole nucleus (Figure 
3B). This finding is particularly interesting in light of the fact that methysergide is an 
ergoline that contains a methyl at the N1 position and yet exhibits antagonist activity at the 
5-HT2B receptor. Moreover, residue 5.46 has been heavily investigated in mutagenesis 
studies at the β-adrenergic receptor as also serving to confer agonist activity with catechol-
containing ligands (Strader et al., 1989), where it forms part of a conserved serine motif in 
TM5. It remains to be seen whether residue 5.46 confers agonist activity at serotonin 
receptors similar to β-adrenergic receptors. In fact, at all 5-HT receptors residue 5.46 is an 
alanine, except at the 5-HT2A and 5-HT6 receptors, where 5.46 is a serine and threonine, 
respectively. Interestingly, an alanine at 5.46 is a known rodent species difference at the 5-
HT2A receptor that likely explains 5-HT2 receptor drug selectivity (Almaula et al., 1996a; 
Johnson et al., 1994).
In TM6, Phe6.51 and Phe6.52 are interacting with the A and B aromatic ring systems of 
ERG in an edge-to-face π-π interaction (Figure 3C). Residue Phe6.52 was first posited to be 
involved in the high affinity binding conformation in the 5-HT2A receptor, because mutation 
of this residue abolishes agonist affinity yet retains antagonist affinity (Choudhary et al., 
1993; Choudhary et al., 1995; Roth et al., 1997). These aromatic residues are located just 
above the conserved Pro6.50 kink of TM6, and are likely involved in the activation process, 
especially as it pertains to the movement of helix 6, which has been demonstrated in the β2 
receptor as important for overall activation.
Lesser understood are polar residues located in TM5, which are conserved at positions 5.42 
and 5.43 for all 5-HT receptors, with notable exceptions at 5-HT2, 5-HT4, and 5-HT6 
receptors. Unique to the 5-HT2 receptors is a glycine present at 5.42, whereas 5.43 is a 
serine. Ser5.43 has been investigated for ligand selectivity at the 5-HT2A receptor, where it 
shows a definitive role for hydrogen bond formation with the 5-methoxy substituent of 
phenethylamines like DOI (Braden and Nichols, 2007), which are selective 5-HT2 ligands, 
and also with possibly 5-HT itself (Johnson et al., 1997). In both the 5-HT1B and 5-HT2B 
crystal structures, ERG lacks a substituent capable of forming a hydrogen bond in this 
region, and in fact, residue 5.43 is interacting with an adjacent polar residue residue at 
position 6.55 in TM6 (Figure 3D). This hydrogen bond between Ser5.43 and Asn6.55 in the 
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5-HT2B receptor likely serves as an anchor for the tight distance between TM5 and 6, which 
has been posited as a possible explanation for ERG’s β-arrestin bias by possible dampening 
of G protein activation (Wacker et al., 2013; Figure 4).
3.2.2 Extended binding site—Compared to the orthosteric site, the extended binding 
sites of the 5-HT1B and 5-HT2B receptors are less similar in their interactions with ERG. 
Overall, the extended binding site encompasses EL2b and also the extracellular portions of 
TM5 and TM7, as well as select residues in TM6. The tripeptide of ERG occupies the site 
between hydrophobic residues located in EL2b and residue 7.35 forming a hydrophobic cleft 
between these two regions of the receptor (Figure 4A). In fact, EL2b and residue 7.35 in 
TM7 can be thought of as a cap or lid forming over the tripeptide of ERG.
Arguably, one of the most important differences between the 5-HT1B and 5-HT2B structures 
with respect to the extended binding site is M5.39 in the 5-HT2B receptor and M6.58 in the 
5-HT1B receptor, which interact with the phenylalanine peptide portion of ERG (Figure 4B), 
yet from opposite sides of the receptor. In fact, residue M5.39 in the 5-HT2B receptor has 
been investigated as determining ligand selectivity, where valine mutation of M5.39 results 
in loss of affinity for norfenfluramine (Setola et al., 2005), the active metabolite of 
fenfluramine. In the 5-HT1B receptor, however, this residue is a smaller, polar Thr, which 
likely allows space for extended bulky 5-substituted tryptamines like the triptan class of 
antimigraine drugs (see Figure 1). It appears therefore, that residue M5.39 would prevent 
binding of larger triptans in the 5-HT2B receptor, thus explaining the lack of 5-HT2B affinity 
and overall safety for the triptan class of antimigraine drugs.
Related to divergence of residue 5.39, residue 6.58 in TM6 is also strikingly different 
between the 5-HT1B and 5-HT2B receptors. In the 5-HT1B receptor, M6.58 interacts with the 
phenyl of the phenylalanine of the tripeptide of ERG causing a shift of this phenyl group 
closer to TM5 (Figure 4B). Comparison of the TM5 and TM6 distances between the two 
receptor structures reveals that in the 5-HT2B receptor these helices are closer than observed 
in the 5-HT1B receptor (Figure 4C), likely a result of these divergent residues 5.39 and 6.58, 
as well as previously discussed residues 5.43 and 6.55.
3.3 Conserved motifs and microswitches
3.3.1 DRY motif—In TM3, the most conserved residue is Arg3.50, which is part of the 
conserved DRY motif (Asp-Arg-Tyr). In the inactive state of rhodopsin, Arg3.50 forms a 
salt bridge to neighboring Asp3.49 (Palczewski et al., 2000), and the DRY motif was 
originally thought to stabilize the ground state of the receptor (Rovati et al., 2007), because 
in photoactivated rhodopsin, the salt bridge between Asp3.49 and Arg3.50 is broken (Salom 
et al., 2006). Mutagenesis studies further support the role of the DRY motif to stabilize the 
ground state of the receptor because mutations of this motif in the 5-HT2A receptor usually 
result in constitutive activity (Shapiro et al., 2002), and mutations of Arg3.50 completely 
abolish measurable G protein activation, at least in muscarinic M1 receptors (Jones et al., 
1995). The crystal structure of the β2 adrenergic receptor-Gs complex also revealed that 
Arg3.50 likely forms a hydrogen bond with Tyr5.58 or with the G protein itself, where the 
Arg3.50 is sandwiched between Tyr5.58 and a Tyr located in the Gs-protein C-terminal tail 
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(Rasmussen et al., 2011) in a cation-π electrostatic interaction. However, the role of the 
DRY motif is still not entirely clear because several GPCRs lack the D(E)RY motif, and 
examination of inactive (antagonist-bound) crystal structures reveal that the Asp3.49 and 
Arg3.50 is indeed broken, as is the case for the β1and β2 adrenergic receptor, A2A, and 
CXCR4 receptors (Cherezov et al., 2007; Jaakola et al., 2008; Warne et al., 2008; Wu et al., 
2010). In fact in the H1 histamine receptor, Arg3.50 forms a novel contact with a Gln 
residue in TM6 (Shimamura et al., 2011). In summary, D(E)RY motif is not entirely 
conserved, but does point to a general mechanism of G protein activation with respect to 
GPCRs.
In the 5-HT1B receptor, this ionic lock between Arg3.50 and Asp3.49 is broken, and 
surprisingly in the 5-HT2B crystal structure, this ionic lock is preserved (Figure 5A). The 
lack of the intact salt bridge suggests that ERG in the 5-HT1B receptor is in a fully active 
state of the receptor, whereas 5-HT2B is not, partially explaining that an intact salt bridge in 
the DRY motif may be indicative of a β-arrestin biased state in the 5-HT2B receptor.
3.3.2 NPxxY motif—The highly conserved NPxxY motif located toward the cytoplasmic 
end of TM7 is thought to be involved in GPCR activation (Nygaard et al., 2009), where the 
conserved Tyr7.53 can move and rotate toward the helical bundle just below the binding 
site. In the β2 adrenergic receptor, 13C-methionine labeling reveals conformational states not 
detected in crystal structures, which argue the existence of a multitude of receptor activation 
states (Nygaard et al., 2013). In this study carvedilol, a β2 adrenergic β-arrestin biased 
ligand, shows a large shift in movement of the cytoplasmic domain of TM7, an area 
containing the NPxxY motif. The NPxxY motif has been implicated as crucial in the 
recruitment of β-arrestin by its movement toward intramembrane helix 8, which contains a 
known phosphorylation site responsible for the binding of arrestin (Gehret et al., 2010). The 
NPxxY motif is thought to form an opening for a water channel to flow through upon 
receptor activation (Yuan et al., 2014) and residue Tyr7.53 is thought of as “gate keeper.”
In both the 5-HT1B and 5-HT2B receptor structures, Tyr7.53 rotates toward the helical core, 
suggestive of a classical active state, but there appears to be more pronounced inward 
rotation of Tyr7.53 in the 5-HT2B structure (Figure 5B). As mentioned, the movement of 
Tyr7.53 and TM7 in general is thought be critical for the arrestin recruitment event moving 
the C-terminus, possibly allowing for phosphorylation and for subsequent arrestin 
recruitment to occur (Shukla et al., 2011). This suggests perturbations in the NPxxY motif 
may be predictive of β-arrestin bias. The finding that the inward rotation and overall 
movement of TM7 toward the core of the 5-HT2B receptor is evidence that the 5-HT2B-ERG 
receptor complex is indeed in a β-arrestin biased state.
3.3.3 P-I-F motif—The most conserved residue in TM5 P5.50 forms the P-I-F motif 
together with I3.40 and F6.44. This motif is only now gaining attention as a critical trigger 
motif for receptor activation, especially in light of the 5-HT1B and 5-HT2B crystal structures. 
These three residues form an interface at the base of the binding pocket and show striking 
differences related to the active versus inactive crystal structures of aminergic GPCRs. For 
example, comparison of active and inactive crystal structures of the β2 adrenergic receptor 
(Rasmussen et al., 2007), an inward shift of TM5 P5.50 leads to a rotamer switch of I3.40 
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resulting in an inward shift of F6.44, overall leading to a rotation of TM6 (Figure 5C). 
Rotation and overall movement of TM6 has been implicated in GPCR activation (Ghanouni 
et al., 2001), especially because the intracellular portion of TM6 forms the interface with the 
G protein (Rasmussen et al., 2011) and shifts 14 Å outward toward the cytoplasmic end 
upon activation.
Residues I3.40 and F6.44 were first proposed to account for active versus inactive states of the 
β2-receptor through in silico simulations (Dror et al., 2011). For the 5-HT1B and 5-HT2B 
crystal structures, the P-I-F motif shows two different configurations, where the 5-HT1B 
resembles the active state of the β2 adrenergic receptor, and the 5-HT2B is posited to be in 
an intermediate state. The 5-HT1B receptor shows an almost identical display of the P-I-F 
motif compared with both active crystal structures of the β2 adrenergic receptor with I3.40 
rotated up toward the extracellular side and F6.44 shifting inward. The 5-HT2B receptor, 
however, shows a similar rotation of I3.40, but does not show the same degree of inward shift 
of F6.44, which is distinct from the inactive crystal structure of the β2 adrenergic receptor, 
suggestive of an intermediate state of activation.
As discussed previously related to the binding pocket, critical residues for manifesting 
agonist activity reside in the TM3, TM5, and TM6 interface, most notably residues 3.37, 
5.46, and 6.52, which allow for high agonist binding affinity. It is conceivable that the P-I-F 
motif serves as an initial relay from the binding pocket to the other trigger motifs, D(E)RY 
and NPxxY. The P-I-F motif is located in close proximity to the binding pocket, and 
therefore can be argued to be a primary trigger motif to recognize ligand-induced 
conformation changes from the binding pocket, thus transducing this shift down to the other 
trigger motifs. This is especially relevant given that ergotamine is a β-arrestin biased agonist 
with very low G protein activation and that the intermediate state of the P-I-F motif 
observed in the 5-HT2B receptor may be indicative or possibly predictive of a biased state of 
the receptor.
3.3.4 Allosteric sodium site—The most conserved residues in TM1 and TM2 are 
Asn1.50 and Asp2.50, which participate in an extensive hydrogen bond network with 
structured waters in rhodopsin (Pardo et al., 2007). Recent evidence indicates that Asp2.50 
also forms part of the sodium ion binding site in the A2A receptor (Liu et al., 2012), and can 
also serve as an efficacy switch for β-arrestin versus G protein signaling in the delta opioid 
receptor (Fenalti et al., 2014). These findings are particularly interesting because the 
presence of sodium in binding buffer was known to inhibit high affinity agonist binding in 
opioid receptors, leaving antagonist affinity intact (Pert et al., 1973). The sodium site as a 
possible allosteric level of control of functional selectivity is now becoming appreciated, and 
it is thought that the sodium ion allosterically alters the binding pocket to dampen G protein 
signaling, leaving β-arrestin recruitment intact. Therefore, the sodium ion may serve as a 
general mechanism for Class A GPCRs to keep the receptor in a low affinity state, and upon 
activation by agonists, the sodium pocket collapses leading to robust G protein signaling 
(Katritch et al., 2014).
In the 5-HT1B and 5-HT2B structures, the resolution is too low to observe the sodium ion, 
but alignment between the delta opioid receptor (DOR) containing the sodium ion and the 
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serotonin receptor structures reveals that the sodium pocket is structurally similar. The 
conserved aspartate in TM2 (D2.50) is present in a similar orientation (Figure 5D), as well 
as W6.48, located across the sodium site in TM6. Some striking differences include the 
conserved serine, S3.39, which is oriented closer to the location of the putative sodium ion 
in the serotonin structures, suggesting the sodium pocket may be contracted or possibly 
collapsed in both 5-HT structures, further supporting the notion that these structures are in 
an active state. Residues 3.35 (F1383.35 in the 5-HT2B and C1323.35 in the 5-HT1B 
receptors) are oriented away from the putative sodium ion and likely provide very little 
coordination. In contrast, the analogous residue N1313.35 in the DOR was found to mediate 
high β-arrestin constitutive activity (Fenalti et al., 2014), which suggests the electronic 
identity and orientation of this residue may impart a bottom to the sodium site preventing the 
escape of sodium, thus balancing the basal state of G protein versus arrestin activity. In 
addition, the 5-HT2B receptor residue S3737.45 located one turn above the NPxxY motif in 
TM7 is oriented much closer to the position of the putative sodium ion, which is in contrast 
to N3607.45 in the 5-HT1B receptor and N3107.45 in the DOR. The close orientation of 
S3737.45 in the 5-HT2B structure into the sodium site suggests that the sodium pocket is 
indeed collapsed. Mutation of this residue imparted an efficacy switch to β-arrestin signaling 
in the DOR (Fenalti et al., 2014), and the close orientation of S3737.45 to the sodium pocket 
further supports the finding that the 5-HT2B structure is in a β-arrestin biased state. 
However, more studies are needed to elucidate fully the effects of sodium on serotonin 
receptor signaling.
3.3.5 Comparison to the muscarinic M2 allosteric site—Recent crystallographic 
evidence for the allosteric site in GPCRs has indicated that the extracellular portions of the 
muscarinic M2 receptor form the binding site for positive allosteric modulator, LY2119620 
(Kruse et al., 2013). In the M2 crystal structure (PDB 4MQS), the orthosteric agonist, 
iperoxo, roughly occupies the same site as the indole nucleus of ERG in the 5-HT2B 
receptor. Most strikingly, however, the allosteric site that LY2119620 occupies is the same 
extracellular region as the tripeptide portion of ERG (Figure 6). These similar poses in both 
the M2 and 5-HT2B receptors suggest that the location of the extracellular allosteric site for 
Class A GPCRs is quite similar, and in fact, argue that ERG likely functions as a bitopic 
ligand; that is it occupies both the orthosteric and putative extracellular allosteric site in the 
serotonin receptor. These similar binding poses open a potential therapeutic avenue for drug 
development of novel serotonin receptor allosteric modulators.
4. Conclusions and future directions
Crystal structures provide a rather static template for the design of novel drugs aimed at 
selectivity among the serotonin receptors. Currently, the 5-HT1B and 5-HT2B crystal 
structures have guided the development of novel compounds selective for the 5-HT1B 
receptor over the 5-HT2B receptor (Rodriguez et al., 2014). In fact, with respect to the 
design of functionally selective ligands, efforts are already underway to understand and 
exploit the extended binding site with molecular modeling, in particular, the dopamine D3 
receptor (Lane et al., 2013).
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One of the greatest challenges facing the design of functionally selective drugs is the lack of 
structural information available for each receptor target. With the recent renaissance in 
GPCR crystallography, however, the molecular mechanisms of GPCR activation are now 
becoming clearer. Examination of GPCR crystal structures in complex with a variety of 
ligands (from full/partial agonists, inverse/silent antagonists) and effectors (e.g. G proteins, 
arrestins, etc.) provide medicinal chemists and molecular pharmacologists with an 
opportunity to design more efficacious drug treatments at their respective receptor targets. 
More importantly, this review focuses on the serotonin 5-HT2B and 5-HT1B receptor crystal 
structures in complex with ergotamine (Wacker et al., 2013), as offering a more focused 
approach to design functionally selective compounds with ligand bias.
The process by which GPCRs activate one pathway over another, however, is still rather 
complex. Using the β2 adrenergic receptor as a prototypical system, progress into overall 
receptor mechanics is still being investigated in regard to ligand sampling of various 
conformational states observed upon agonist versus inverse agonist activated receptors 
(Nygaard et al., 2013). However, our insights into the molecular mechanics of receptor 
activation are still rather limited, because crystal structures provide only a “snapshot” of the 
receptor’s lowest energy state (Katritch et al., 2013). Currently, crystal structures of Class A 
GPCRs reveal that several conformations exist that correlate with in vitro pharmacology 
profile of the complexed ligand. These additional receptor states or conformations are now 
being equated with biased states of the receptor as detected by NMR in the β2 adrenergic 
receptor (Nygaard et al., 2013). Therefore, the plethora of such “active” receptor states 
seems immense and possibly exploitable by understanding the structure-activity-
relationships (SAR) of druggable ligands that give rise to such states. In the future, advanced 
structural biology methods including NMR (Ding et al., 2013) and X-ray free electron laser 
(XFEL) diffraction (Deupi, 2013) will likely lead to a greater understanding into the 
dynamics of receptor activation. In fact, the structure of the 5-HT2B receptor has been 
recently solved using serial femtosecond XFEL diffraction, and shows remarkable similarity 
to the crystal structure obtained by X-ray diffraction, with the notable exceptions of the 
intracellular and extracellular loops (Liu et al. 2013). Hopefully, future structures using 
XFEL diffraction will resolve conformational states of the receptor in a biased state, and 
possibly identify new conformations not yet observed with X-ray crystallography.
In summary, the crystal structure of the serotonin 5-HT2B receptor in complex with 
ergotamine, a β-arrestin biased ligand, provides SAR clues to the molecular determinants of 
functionally selective biased ligands (Wacker et al., 2013). The 5-HT2B crystal structure 
reveals an intermediate state of activation stabilized by the extracellular-facing tripeptide 
portion of ergotamine, which likely drives β-arrestin bias and is not present on unbiased 
ligands such as serotonin itself. This tripeptide portion interacts with the extracellular end of 
TM6 and the C-terminal portion of EL2 (Figure 4), forming the extended binding site of the 
receptor, as previously discussed. Also previously discussed is that the extended binding site 
overlaps with the allosteric site of the M2 muscarinic receptor (Figure 6), implicating 
ergotamine is a bitopic ligand. That suggests that the tripeptide portion of the ergotamine 
can serve as starting point for the design of not only functionally selective ligands, but also 
functionally selective allosteric ligands, which are potentially capable of superior therapeutic 
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utility. Overall, these crystal structures provide much needed insight into novel therapeutics 
incorporating biased signaling for a number of serotonin-related diseases.
Methods used for generation of GPCR alignments
Figures utilized the 5-HT1B and 5-HT2B crystal structures with ERG bound (Wang et al. 
2013; Wacker et al. 2013), and also the muscarinic M2 receptor crystal structure with 
iperoxo and LY2119620 bound (Kruse et al. 2013). All structures were downloaded from 
the Protein Data Bank (5-HT1B PDB code 4IAR; 5-HT2B PDB code 4IB4; M2 PDB code 
4MQT). Using only the GPCR and complexed ligand, structures were aligned using the 
PyMOL Molecular Graphics System, Version 1.1 Schrödinger, LLC.
Abbreviations
5-HT 5-hydroxytryptamine, serotonin
GPCR G protein coupled receptor
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Figure 1. 5-HT receptor ligands
Shown are the structures of 5-hydrotryptamine (5-HT or serotonin) and ergolines, lysergic 
acid diethylamide (LSD), ergotamine (ERG), and dihydroergotamine (DHE), which are 
ligands at all serotonin receptors. Also shown is an example triptan ligand, sumatriptan, 
which posseses 5-HT1B receptor selectivity and also norfenfluramine, the active metabolite 
of fenfluramine, which possesses 5-HT2B agonist activity.
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Figure 2. ERG occupies both the orthosteric and extended binding sites in 5-HT1B and 5-HT2B 
receptors
Ergotamine (ERG) occupies two distinct sites in both the 5-HT1B and 5-HT2B receptors, the 
orthosteric site, where the indole nucleus of ERG resides, and the extended binding site, 
where the tripeptide portion is engaged.
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Figure 3. Orthosteric sites of the 5-HT1B and 5-HT2B receptor crystal structures
Alignment of the 5-HT1B (purple) and 5-HT2B (blue) crystal structures reveals similar 
binding poses for ERG in the orthosteric binding pocket. A) Conserved aspartate (D3.32) 
forms a salt bride with protonated N6 of ERG and is also coordinated with residue 3.36. 
D3.32 also forms a hydrogen bond with Y7.43. B) Conserved residues, T3.37 and A5.46, 
engage the indole N-H portion of ERG. C) Aromatic residues F6.51, F6.52 and W6.48 
involved in an edge-to-face π-π stacking with the ring system of ERG. D) Polar residues 
5.43 and 6.55 involved in an interhelical hydrogen bond between TM5 and TM6, which are 
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the putative residues for 5-hydroxy recognition of 5-HT. E) Summary of residue interactions 
with ERG in the orthosteric site.
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Figure 4. Extended binding sites of the 5-HT1B and 5-HT2B receptor crystal structures
Alignment of the 5-HT1B (purple) and 5-HT2B (blue) crystal structures reveals similar yet 
strikingly different poses for ERG in the extended binding site of the binding pocket. A) 
Tripeptide portion of ERG forms similar interactions with nonpolar contacts in EL2 and 
residue 7.35 B) Rotamer state of tripeptide phenyl differs depending on presence of 
methionine at either 5.39 (5-HT2B) or 6.58 (5-HT1B) C) TM5 is pushed toward TM6 in 5-
HT2B receptor compared to the 5-HT1B receptor, likely a result of the tripeptide phenyl 
rotamer state D) Summary of residue interactions with ERG in the extended binding site.
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Figure 5. Microswitch trigger motifs of the 5-HT1B and 5-HT2B receptor crystal structures
The 5-HT1B (purple) and 5-HT2B (blue) crystal structures show select differences in their 
trigger motifs. A) Ionic lock between Asp3.49 and Arg3.50 in the DRY motif is broken in 
the 5-HT1B structure but intact in the 5-HT2B structure, suggestive of an inactive state. B) In 
the NPxxY motif, movement of Tyr7.53 toward the helical bundle is more pronounced in 
the 5-HT2B structure compared to the 5-HT1B structure. C) Inward movement of Phe6.44 in 
the P-I-F trigger motif is only present in the 5-HT1B structure. D) Sodium (purple) in the 
sodium site in the DOR (orange) aligned with 5-HT structures show a condensed or 
collapsed sodium pocket in both 5-HT structures.
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Figure 6. Tripeptide portion of ERG occupies a site overlapping with the allosteric modulator, 
LY2119620, in the muscarinic M2 receptor
Alignment of the 5-HT2B (blue) and muscarinic M2 (green; PDB 4MQS) receptor crystal 
structures show that M2 orthosteric agonist iperoxo (IPX) and the ergoline nucleus of ERG 
occupy the same site deep in the helical bundle. Similary, the tripeptide portion of ERG and 
M2 allosteric modulator, LY2119620 (LY), also occupy the same site encompassing the 
extracellular portion of the receptor.
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